RGNX — REGENXBIO Inc.

Summary of REGENXBIO (RGNX) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• REGENXBIO reported its financial results for Q1 2026, with specifics not detailed in the transcript. However, the company highlighted ongoing operational execution and progress in its clinical programs.
• The company anticipates a $100 million milestone payment from AbbVie upon dosing the first patient in a Phase IIb trial for diabetic retinopathy.

2. Strategic Updates and Business Highlights

• REGENXBIO announced positive top-line data from the pivotal AFFINITY DUCHENNE trial for RGX-202, a gene therapy for Duchenne muscular dystrophy (DMD), which met its primary endpoint with high statistical significance.
• The trial has dosed over 50 patients, with plans to reach 60 by mid-2026, supporting a potential FDA approval in 2027.
• The partial clinical hold on RGX-121 for Hunter syndrome has been lifted, and the company is actively engaging with the FDA regarding its path forward.
• The company is focused on delivering multiple first and best-in-class gene therapies, with RGX-202 being a key candidate.

3. Forward Guidance and Outlook

• REGENXBIO is positioning RGX-202 for potential accelerated approval in 2027, leveraging strong correlations between microdystrophin expression and functional improvements observed in patients.
• The company plans to file for regulatory approval in the first half of 2027, with expectations of having a robust safety database of approximately 50 patients by that time.

4. Bad News, Challenges, or Points of Concern

• The company faces challenges related to regulatory discussions with the FDA, particularly regarding the necessity of a randomized controlled trial (RCT) for accelerated approval. There is concern that the FDA may require additional data, which could delay the approval process.
• There were two treatment-related serious adverse events (SAEs) reported, including one case of myocarditis and one of liver injury, though both were managed effectively and resolved without long-term effects.
• The competitive landscape for gene therapies remains intense, and the company must navigate the evolving regulatory environment and patient expectations.

5. Notable Q&A Insights

• Analysts inquired about the correlation between microdystrophin expression and functional outcomes, with experts expressing confidence in the data showing a strong relationship.
• There was discussion on the sophistication of patient families regarding gene therapy options, highlighting their need for transparent communication about risks and benefits.
• The FDA's feedback on the necessity for a randomized trial was clarified, with the company indicating that they are prepared to pivot their confirmatory study if required.
• The panel of physicians expressed comfort with the immunosuppressive regimen used in the trial, noting its favorable safety profile compared to other therapies in the field.

Overall, REGENXBIO's Q1 2026 earnings call showcased significant progress in its clinical programs, particularly RGX-202, while also addressing regulatory challenges and the need for ongoing patient engagement and education.